Show simple item record

dc.contributor.authorMotahhari Moghaddam, Alien
dc.date.accessioned2020-01-30T22:09:06Z
dc.date.available2020-01-30T22:09:06Z
dc.identifier.urihttp://hdl.handle.net/1974/27580
dc.description.abstractThe development of an angiogenic drug delivery system requires in vitro and in vivo testing before the system can used to treat a disease or condition. The zebrafish embryo is a promising animal model for screening potential angiogenic drug delivery systems due to their optical transparency, which allows for the live imaging of tissues and biological responses. Following establishment of injection protocols, the trunk and yolk sac of 2 - 3 day post-fertilization (dpf) embryos were investigated as potential implant sites for evaluating angiogenic responses due to the highly ordered and easily visualized vasculature at these locations. Bolus injections of vascular endothelial growth factor A(VEGF-A) was carried out into the yolk sac of Tg[fli1a:DsRED] zebrafish embryos and the survival rate and angiogenic response in the neighboring gut vasculature was evaluated, and microparticle retention rates within the trunk and yolk sac were analyzed. Embryos that received the VEGF-A bolus injections had a survival rate of 100%, and the survival rate of embryos that received a vehicle only injection was also 100%. No angiogenic response was detected in the surrounding vasculature. The microparticle retention rate of 25 μm PE microparticles injected into the yolk sac was poor, where only 7% of injected microparticles were retained in the yolk sac after 2 days. The trunk injection model was evaluated for microparticle retention rates using 10 μm polystyrene microparticles and 3 dpf Tg[fli1a:DsRED] embryos. At 2 days post-injection (dpi), 56% of the injected microparticles remained within the injection sites. A simple VEGF-A delivery system was made by adsorbing the protein to the surface of 15 μm PLGA microparticles. In vitro release studies showed that this system released 0.042 μg VEGF-A/mg microparticle/hr and that 100% of the loaded protein was released after 48 hours. The VEGF-A-loaded microparticles were injected into the trunk of 3 dpf (Tg[fli1a:DsRED]) embryos. Qualitative and quantitative analysis of the intersegmental vessels in proximity to the injection site showed no change in the vasculature between the VEGF-A injection groups and the two control groups injected with either 15 μm PLGA particles and a solution of PBS.en
dc.language.isoengen
dc.relation.ispartofseriesCanadian thesesen
dc.rightsCC0 1.0 Universalen
dc.rightsQueen's University's Thesis/Dissertation Non-Exclusive License for Deposit to QSpace and Library and Archives Canadaen
dc.rightsProQuest PhD and Master's Theses International Dissemination Agreementen
dc.rightsIntellectual Property Guidelines at Queen's Universityen
dc.rightsCopying and Preserving Your Thesisen
dc.rightsThis publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.en
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/
dc.subjectBiomedical Engineering, Drug delivery, Zebrafishen
dc.titleDevelopment of a Screening Platform for Angiogenic Drug Delivery Systems Using Zebrafish Embryosen
dc.typethesisen
dc.description.degreeM.A.Sc.en
dc.contributor.supervisorFitzpatrick, Lindsayen
dc.contributor.departmentChemical Engineeringen
dc.degree.grantorQueen's University at Kingstonen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC0 1.0 Universal
Except where otherwise noted, this item's license is described as CC0 1.0 Universal